17888-55-0Relevant academic research and scientific papers
C-F bond cleavage enabled redox-neutral [4+1] annulation via C-H bond activation
Wang, Cheng-Qiang,Ye, Lu,Feng, Chao,Loh, Teck-Peng
supporting information, p. 1762 - 1765 (2017/02/15)
Using α,α-difluoromethylene alkyne as a nontraditional one-carbon reaction partner, a synthetically novel method for the construction of isoindolin-1-one derivatives via Rh(III)-catalyzed [4+1] annulation reaction is reported. The 2-fold C-F bond cleavage not only enables the generation of desired product under an overall oxidant-free condition but also results in a net migration of carbon-carbon triple bond. In addition, the present reaction protocol exhibits a tolerance of a wide spectrum of functional groups due to the mild reaction conditions employed.
Rhodium-catalyzed C-H alkynylation of arenes at room temperature
Feng, Chao,Loh, Teck-Peng
supporting information, p. 2722 - 2726 (2014/03/21)
The rhodium(III)-catalyzed ortho C-H alkynylation of non-electronically activated arenes is disclosed. This process features a straightforward and highly effective protocol for the synthesis of functionalized alkynes and represents the first example of merging a hypervalent iodine reagent with rhodium(III) catalysis. Notably, this reaction proceeds at room temperature, tolerates a variety of functional groups, and more importantly, exhibits high selectivity for monoalkynylation. Hot rhod: A rhodium-catalyzed, electronically reversed Sonogashira reaction between unbiased arenes and the hypervalent iodine reagent 1 proceeds through C-H activation. This reaction displays excellent functional-group tolerance and high efficiency, and thus opens a new synthetic pathway to access functionalized alkynes. Cp=C5Me5, DCE=1,2-dichloroethane, Piv=pivaloyl, TIPS=triisopropylsilyl.
Antitumor Activity of 5-Aryl-2,3-dihydroimidazoisoquinolines
Houlihan, William J.,Munder, Paul G.,Handley, Dean A.,Cheon, Seung H.,Parrino, Vincent A.
, p. 234 - 240 (2007/10/02)
A series of 5-aryl-2,3-dihydroimidazoisoquinolines previously reported to be platelet activating factor (PAF) receptor antagonist were evaluated for potential antitumor activity.Several compounds, such as the 5-(4'-tert-butylphenyl) (65), 5- (69), and 5-(4'-cyclohexylphenyl) (71) analogs showed very good cytotoxicity against several tumor cell lines. 5--2,3-dihydroimidazoisoquinoline (SDZ 62-434, 53) was more effective on a milligram per kilogram basis than the clinical cytostatic agent edelfosine (1) in increasing survivors and decreasing tumor volume in the oral mouse Meth A fibrosarcoma assay.It was selected for further development and is currently in phase I clinical trials in cancer patients.
